Clinical Trials · NCT07503210

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Name: AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 3Amycretin

Phase: Phase 3
Recruitment status: Active Not Recruiting
Sponsor: Novo Nordisk A/S
Enrollment: 606
Start date: Apr 2026
Locations: 72 sites, 12 countries
Primary endpoint: Relative change in body weight

View Amycretin compound reference